Jefferies Initiates Coverage On Viatris with Hold Rating, Announces Price Target of $11
Jefferies analyst Glen Santangelo initiates coverage on Viatris (NASDAQ:VTRS) with a Hold rating and announces Price Target of $11.
Reported Early October 11, ‘Viatris Considers Sale of $3B European OTC Assets’ – Bloomberg News
Viatris Said to Weigh Sale of $3 Billion European OTC Assets - Bloomberg
Viatris Inc. is considering a potential sale of its consumer-health assets in Europe, in a deal that could fetch more than €3 billion
US Supreme Court Turns Away Biogen’s Last Effort To Reinstate Tecfidera Patent
The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera.
Mapi Pharma Announces Top-Line Results From GA Depot Phase III Trial For Relapsing Forms Of Multiple Sclerosis; Says Study Met Primary Endpoint
The study met its primary endpoint showing that GA Depot 40 mg statistically significantly reduced the annualized relapse rate (ARR) by 30.1 percent compared to placebo (p=0.0066)
Looking Into Viatris’s Return On Capital Employed
Pulled from Benzinga Pro data, Viatris (NASDAQ:VTRS) posted Q2 earnings of $313.90 million, an increase from Q1 of 21.37%. Sales dropped to $4.12 billion, a 1.79% decrease between quarters.
FDA Alerts Patients, Caregivers, And Health Care Providers Of Cross-Compatibility Issues With Autoinjector Devices That Are Optional For Use With Glatiramer Acetate Injection
Received Reports That Using Autoinjector Not Compatible With Specific Glatiramer Acetate Injection Drug Product Resulted In Missed, Partial Doses
BMO Capital Maintains Outperform on Viatris, Lowers Price Target to $16
BMO Capital analyst Gary Nachman maintains Viatris (NASDAQ:VTRS) with a Outperform and lowers the price target from $19 to $16.